Rapid detection of common CARD15 variants in patients with inflammatory bowel disease

Molecular Diagnosis

Volumn 8, Issue 2, 2004, Pages 101-105

  Roberts, Rebecca L ^a   Gearry, Richard B ^a   Barclay, Murray L ^a   Kennedy, Martin A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; DNA; MAGNESIUM CHLORIDE; PRIMER DNA; TAQ POLYMERASE;

ACCURACY; AMPLIFICATION REFRACTORY MUTATION SYSTEM ASSAY; ARTICLE; ASSAY; CARD15 GENE; CAUCASIAN; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DIAGNOSTIC VALUE; ENTERITIS; GENE; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; QUALITY CONTROL; RELIABILITY; RESEARCH; RISK FACTOR; SEQUENCE ANALYSIS; VALIDATION PROCESS;

DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMERASE CHAIN REACTION;

EID: 5444233149     PISSN: 10848592     EISSN: None     Source Type: Journal    
DOI: 10.2165/00066982-200408020-00004     Document Type: Article

References (35)

1. Podolsky DK. The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2002; 16 (6): 933-43
2. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12 (8): 855-62
3. Somerville KW, Logan RF, Edmond M, et al. Smoking and Crohn's disease. BMJ (Clin Res Ed) 1984; 289 (6450): 954-6
4. Corrao G, Tragnone A, Caprilli R, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breaslfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol 1998; 27 (3): 397-404
5. Card T, Logan RF, Rodrigues LC, et al. Antibiotic use and the development of Crohn's disease. Gut 2004; 53 (2): 246-50
6. Ekbom A, Montgomery SM. Environmental risk factors (excluding tobacco and microorganisms): critical analysis of old and new hypotheses. Best Pract Res Clin Gastroenterol 2004; 18 (3): 497-508
7. Feeney MA, Murphy F, Clegg AJ, et al. A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14 (5): 529-34
8. el-Omar E, Penman I, Cruikshank G, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 1994; 35 (10): 1385-8
9. Parente F, Molteni P, Bollani S, et al. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases: a cross-sectional study with matching. Scand J Gastroenterol 1997; 32 (11): 1140-6
10. Orholm M, Binder V, Sorensen TI, et al. Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study. Scand J Gastroenterol 2000; 35 (10): 1075-81
11. Thompson NP, Driscoll R, Pounder RE, et al. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996; 312 (7023): 95-6
12. Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut 1988; 29 (7): 990-6
13. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411 (6837): 603-6
14. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411 (6837): 599-603
15. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276 (7): 4812-8
16. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3 (5): 371-82
17. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278 (11): 8869-72
18. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70 (4): 845-57
19. Yang SK, Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001; 7 (3): 260-70
20. Sonnenberg A, Wasserman IH. Epidemiology of inflammatory bowel disease among US military veterans. Gastroenterology 1991; 101 (1): 122-30
21. Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002; 123 (1): 86-91
22. Cavanaugh JA, Adams KE, Quak EJ, et al. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann Hum Genet 2003; 67 (Pt 1): 35-41
23. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis 2003; 9 (5): 281-9
24. Buning C, Genschel J, Buhner S, et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004; 19 (10): 1073-8
25. Guo QS, Xia B, Jiang Y, et al. NOD2 3020insC frameshift mutation is not associated with inflammatory bowel disease in Chinese patients of Han nationality. World J Gastroenterol 2004; 10 (7): 1069-71
26. Hampe J, Cuthbert A, Croitcher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357 (9272): 1925-8
27. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359 (9318): 1661-5
28. Helio T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familiarly occurring and complicated forms of Crohn's disease. Gut 2003; 52 (4): 558-62
29. Linde K, Boor PP, Houwing-Duistermaat JJ, et al. Card15 and Crohn's disease: healthy homozygous carriers of the 3020insC frameshift mutation. Am J Gastroenterol 2003; 98 (3): 613-7
30. Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71 (1): 74-83
31. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (4): 395-400
32. Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem 1988; 174 (2): 485-8
33. Sugimura K, Taylor KD, Lin YC, et al. A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet 2003; 72 (3): 509-18
34. Palmieri O, Toth S, Ferraris A, et al. CARD15 genotyping in inflammatory bowel disease patients by multiplex pyrosequencing. Clin Chem 2003; 49 (10): 1675-9
35. Vermeire S. NOD2/CARD15: relevance in clinical practice. Best Pract Res Clin Gastroenterol 2004; 18 (3): 569-75